Viatris Blepharitis Drug Fails in Phase III, Future Uncertain

Viatris’ investigational blepharitis therapy, MR-139 (pimecrolimus 0.3% ophthalmic ointment), failed to meet the primary endpoint of complete debris resolution in a Phase III trial involving 477 patients. The six-week study assessed twice-daily dosing in patients with blepharitis, a chronic inflammatory eye condition caused by clogged eyelid glands. Following the disappointing results, Viatris announced it is evaluating the future of the programme, potentially altering plans for further Phase III studies. The failure triggered a 4.2% drop in Viatris’ stock. Pimecrolimus, previously approved for dermatological conditions, has not received ophthalmic approval. Despite this setback, Viatris recently saw success with other ophthalmic candidates, including MR-142 and its phentolamine solution for presbyopia. Current blepharitis treatments include topical and oral antibiotics and steroids, with Tarsus’ Xdemvy (lotilaner) emerging as a targeted therapy for Demodex-related blepharitis. Xdemvy is forecast to become a blockbuster drug by 2030, with projected global sales exceeding $1 billion.

21-07-2025